This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hao, C.-Y. Articles by Chen, L.-C. Search for Related Content PubMed PubMed Citation Articles by Hao, C.-Y. Articles by Chen, L.-C.

Alteration of Gene Expression in Macroscopically Normal Colonic Mucosa from Individuals with a Family History of Sporadic Colon Cancer

California Pacific Medical Center Research Institute, San Francisco, California

Requests for reprints: Ling-Chun Chen, California Pacific Medical Center Research Institute, 475 Brannen Street, Suite 220, San Francisco, CA 94107. Phone: 415-600-1745; Fax: 415-600-1390; E-mail: chenlc{at}sutterhealth.org.

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Purpose: We have shown that the expression of several genes associated with human colon cancer is altered in the morphologically normal colonic mucosa (MNCM) of APC^min mice and humans with colon cancers. To determine whether these alterations also occur in the MNCM of individuals who have not developed colon cancer but are at high risk of doing so, we measured gene expression in the MNCM of individuals with a family history of colon cancer.

Methods: Expression of 16 genes in the MNCM of 12 individuals with a first-degree relative with sporadic colon cancer and 16 normal controls were measured by quantitative reverse transcription-PCR. All subjects tested had normal colonoscopic examinations. Biopsy samples of MNCM were obtained from the ascending, transverse, descending, and rectosigmoid regions of the colon (2-8 biopsy samples were obtained from each region).

Results: Relative to normal controls, the expression of several genes, including PPAR-, SAA1, and IL-8 were significantly altered in the macroscopically normal rectosigmoid mucosa from individuals with a family history of colon cancer.

Conclusions: Molecular abnormalities that precede the appearance of adenomatous polyp are present in the MNCM of individuals who have a family history of colon cancer. This observation raises the possibility of screening for individuals who are at an increased risk of developing colon cancer by analysis of gene expression in rectosigmoid biopsy samples. To assess this possibility, prospective studies will be needed to determine whether or not altered gene expression is associated with the subsequent development of adenomatous polyps and/ or colonic carcinomas.

Key Words: colorectal cancer • premalignant lesions • Gastrointestinal cancers: colorectal

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The adenomatous polyp (AP) is a precursor lesion of colon cancer. Early detection and removal of AP has been shown to substantially reduce mortality from colon cancer (1). Currently, colonoscopy is routinely recommended for individuals ages >50 years (1). However, the inconvenience of the precolonoscopy preparation and the high cost of colonoscopy discourage compliance in the general population (2). A less taxing and less expensive method that allows early detection of APs and occult colon cancer, using biomarkers would be useful.

Early detection of AP and colon cancer may be facilitated by identifying the molecular alterations associated with early tumorigenesis. Although the expression of many genes is altered in colon cancers (3–8), it is not clear whether these alterations involve initiation and progression of the cancer, or are a consequence of genomic destabilization. This distinction must be made on precancerous colon mucosa.

The APC^min mouse, which carries a mutation in the adenomatous polyposis coli (APC) gene, is the best-characterized mouse colonic neoplasia model. It is analogous to the human familial adenomatous polyposis syndrome (9). Because APC^min mice always develop intestinal APs within the first 6 months of life, it is reasonable to assume that molecular changes occur in their morphologically normal colonic mucosa (MNCM) before the appearance of any APs. In a previous study, we analyzed the expression of 15 genes in the APs and MNCM from APC^min mice, as well as in MNCM from human colon cancer resection specimens (10). These 15 genes function in several pathways related to cancer development, including the APC/ß-catenin pathway, the NFB pathway, cell cycle, and inflammation and therefore may represent the much larger set of genes that are altered in colon cancer. Expression of 13 of these 15 genes was altered in the APs from APC^min mice. The five genes (CXCR2, Gro-Gro-, MIP-2, COX-2, and OPN) that were most highly up-regulated in mouse APs were also significantly up-regulated in polyp-free colon mucosa. Similarly, we found that expression of 9 of the 15 genes was also altered significantly in morphologically normal mucosa of surgical sections taken from human cancer patients, relative to colonic mucosa from individuals without cancer (10). Of the nine genes that showed altered expressions in the MNCM from patients with rectosigmoid cancers, expressions of PPAR-, PPAR-, and p21^cip/waf1 were down-regulated and expressions of IL-8, OPN, COX-2, CXCR2, MCSF-1, and CD44 were up-regulated (10).

These findings indicate that MNCM from APC^min mice and human with colon cancer is not metabolically normal. We postulate that these changes occur early in the process of colon carcinogenesis (i.e., before the development of APs or cancer), and that these alterations in MNCM may indicate an increased risk of developing colon cancer.

Individuals with a family history of colon cancer are known to have an increased risk of developing colon cancer (11). In this study, we test our hypothesis by analyzing expression levels for 16 genes in MNCM from individuals who had normal colonoscopic examinations and who did not have a prior history of colon cancer. The study group was divided into those with and those without a family history of colon cancer. We found that expression of several genes that were altered in MNCM from colon cancer patients were also altered in the rectosigmoid mucosa from individuals with a family history of colon cancer. Our results suggest that molecular abnormalities are present in the MNCM of the individuals who are at increased risk of developing colon cancer. Because these molecular alterations are present in the absence of APs, they may represent changes contributing to the very early stages of colon carcinogenesis.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Human Subjects. Biopsies of MNCM from the rectum and sigmoid colon were done at the time of routine colonoscopy from individuals seen at the California Pacific Medical Center who had no history of prior colon cancer and who were free of APs, colon cancer, or other colonic lesions at the time of examination. Twelve individuals with a family history of colon cancer in a first-degree relative (Table 1) and 16 individuals with no known family history of colon cancer were included in the study. Although the information of family cancer history is obtained by patients' self-reports without confirmation from the hospital's cancer registry, a recent study has confirmed the accuracy of self-reported family history with regard to colon cancer (12). Of the 12 individuals with a family history of colon cancer, two are mother and daughter (cases 6 and 7 in Table 1), two are sister and brother (cases 11 and 12), and the rest are not related. Study subjects ranged in age from 18 to 64 years in the group with a family history of colon cancer, and 16 to 83 years in the control group (the 16-year-old had undergone colonoscopy for chronic abdominal pain). The research protocols for obtaining normal biopsy specimens for study were approved by the California Pacific Medical Center Institutional Review Board. The appropriate procedure for obtaining informed consent was followed for all study subjects.

View this table: [in this window] [in a new window]   Table 1 Summary of expression of PPAR-, IL-8, SAA1, COX-2, and PPAR- in rectosigmoid biopsy samples from individuals with a family history of colon cancer

Analysis of Gene Expression. The expression levels of oncogene c-myc, CD44 antigen (CD44), cyclooxygenase 1 and 2 (COX-1 and COX-2), cyclin D1, cyclin-dependent kinase inhibitor (p21^cip/waf1), interleukin 8 (IL-8), interleukin 8 receptor (CXCR2), osteopontin (OPN), melanoma growth stimulatory activity (Gro/MGSA), GRO3 oncogene (Gro), macrophage colony stimulating factor 1 (MCSF-1), peroxisome proliferative activated receptor , , and (PPAR-, PPAR-, and PPAR-), and serum amyloid A1 (SAA1) were analyzed by quantitative reverse transcription-PCR. Except for SAA1, the same 15 genes had been analyzed in our previous studies of APC^min mice and colon cancer patients (10). Quantitative reverse transcription-PCR were carried out as described in our previous study (10). In brief, the cycle numbers (C_T) were recorded when the accumulated PCR products crossed an arbitrary threshold. To normalize this value, C_T was determined as the difference between the C_T for each gene tested and the C_T for ß-actin. The average C_T for each gene in the control group was calculated. The C_T was determined as the difference between the C_T for each individual sample and the average C_T for this gene obtained from the control samples. These C_T values were then used to calculate relative gene expression values as described (Applied Biosystems, Foster City, CA, User Bulletin 2, December 11, 1997). All PCR were done in duplicate when cDNA samples were available. The results were also verified using histidyl-tRNA synthetase as internal control (10). Relative gene expression values yielded similar results using either ß-actin or his-tRNA synthetase as reference. Statistical analyses reported here were obtained using ß-actin as normalization controls.

Statistical Analysis. Gene expression patterns were compared between individuals with a family history of colon cancer and the control group subjects who had no family history of colon cancer. Rather than testing expression of each gene separately and adjusting for multiple comparisons by methods that reduce statistical power, we tested the expression patterns of all genes by multivariate ANOVA with Wilks' lambda criterion. This test is a multivariate analogue of the F test for univariate ANOVA, which tests the equality of means. This type of analysis takes into account correlations among gene expression levels and controls the false-positive rate by providing a single test of whether the expression patterns, based on all the genes in the subset, differ between groups.

If there was evidence that expression patterns differed between groups, we used univariate t tests to determine which genes were contributing to the global difference. All multivariate ANOVA tests were based on the Wilks' lambda criterion and were carried out on log (base 2) of the expression levels, because this transformation was required to achieve normal distributions. Our data consisted of a variable number of samples per subject with different numbers of individuals per group (family history versus no family history). The analysis included random effects terms for individuals within group and for samples within individuals to account for the sampling scheme. If Y_ijk denotes a log₂ gene expression value for the kth sample from the jth patient from the ith group, the statistical model is described mathematically by the equation: Y_ijk = M + A_i + B_ij + e_ijk, where A_i is the (fixed) group effect, B_ij is the (random) patient effect, and e_ijk is the (random) sample within patient effect.

We also tested whether or not the magnitude of the differential expression (overexpression or underexpression) increased along the colon from the ascending portion toward rectum, by defining a variable with value 1 for samples from the ascending, 2 for samples from the transverse, 3 for samples from the descending, and 4 for samples from the rectosigmoid portion of the colon. This variable was added to the model so that its effect could be tested for certain genes using univariate ANOVA.

Definition of Cutoff Point. The log₂ of the expression levels of all the biopsy samples from the control group was used to calculate the cutoff point for either up-regulation or down-regulation of each gene. A table of tolerance bounds for a normal distribution was used to define cutoff points so that a fraction of the distribution of no more than P would lie above the cutoff point for up-regulated genes or below the cutoff point for down regulated genes. Each cutoff point was defined by cutoff point = mean + k (SD), where the mean and SD are based on values from the control group. Values of k are found in the table and depend on the P and the number of normal samples (13). Assuming a Gaussian distribution of expression levels of each gene, one would expect <1% of the biopsies from a normal population to have an expression level exceeding the 99% tolerance limit (P = 0.01).

To calculate the probability that the number of observed samples outside the upper 99th percentile was due to chance in each case, we used the binomial distribution method with P = 0.01 and n = the number of samples for each case multiplied by the number of genes tested. For example, for case 1 (Table 1) we had two samples; both showed abnormal expression for PPAR- and SAA1, one of two for PPAR-, and neither was abnormal for IL-8 and COX-2. Thus, for this case, 5 of 10 tested were beyond the upper 0.01 boundary. The probability that this happened by chance is 2.4 x 10^–8. The general formula is given by: where k is the number beyond the 99th percentile and n is the number of samples (5 is the number of genes tested).

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Altered Gene Expression in the Rectosigmoid Mucosa of Individuals with a Family History of Colon Cancer. Twelve individuals (10 women and 2 men) comprised the group with a family history of colon cancer; 16 individuals (9 women and 7 men) served as the control group. We analyzed a total of 92 ascending colon biopsy samples, 85 transverse colon samples, 94 descending colon biopsy samples, and 181 rectosigmoid biopsy samples for levels of expression of 16 genes. Expressions of these genes are known to be altered in the late stages of human colon cancers. We have also shown that some of these genes are altered in the MNCM from surgical resections of colon cancer patients (10).

Multivariate analysis of the expression values of all 16 genes indicated a significant difference in the biopsy samples from the rectosigmoid region (P = 0.01) between those with and those without a family history of sporadic colon cancer. Gene expression in biopsy samples from the descending, ascending and transverse colon did not vary significantly between these two groups of individuals (P = 0.06, 0.22, and 0.52, respectively). Most of the differences in rectosigmoid biopsy samples were contributed by just five of these genes (Table 2): PPAR-, SAA1, IL-8, COX-2, and PPAR-. Similar to the alterations of gene expression in the MNCM of cancer patients (10), we found that the expression levels of SAA1, IL-8, and COX-2 were up-regulated and those of PPAR- and PPAR- were down-regulated in the MNCM of individuals with a family history of sporadic colon cancer.

Comparison with Cutoff Points for "Normal" Gene Expression. Relative gene expression levels in the rectosigmoid samples varied among individuals, much more so in samples obtained from the individuals with a family history of colon cancer than the corresponding values from the controls (Table 2). We therefore use the expression level of each gene in the control group to define the "normal" expression level for each gene by calculating a cutoff point (P = 0.01) for each gene. Figure 1 shows the distribution of the log₂ expression values for genes, PPAR-, IL-8, SAA1, and COX-2 and their cutoff points. As expected, <1% of the biopsy samples from the control group had expression of these genes above or below the cutoff lines (P = 0.01, Fig. 1). However, 21%, 12%, and 8% of the biopsy samples from the family history group had expression of SAA1, IL-8, and COX-2, respectively, above the cutoff points and 12% of them had expression of PPAR- below the cutoff point (Table 3).

View larger version (35K): [in this window] [in a new window]   Fig. 1 Gene expression in rectosigmoid biopsy samples from normal individuals and individuals with a family history of colon cancer. Control group (crosses) or family history group (circles) in each column are different rectosigmoid biopsy samples. log2 expression level of each gene is used (y-axis). The average expression level of each gene in the control group is set at 1; thus, the log2 of the average expression level in the control group of each gene equals 0 on the y-axis. Ninety-nine percent tolerance limits of each gene (dashed lines).

PPAR-

Expression of Different Genes Are Altered at Different Sites of MNCM from Individuals with a Family History of Colon Cancer. Analysis of individual cases from the family history group showed that different genes were altered in rectosigmoid biopsy samples in different subjects. For instance, SAA1 and PPAR- were altered in case 3, IL-8 and SAA1 were altered in case 4, whereas COX-2 and IL-8 but not SAA1 were altered in case 8 (Fig. 2A). In addition, some genes were altered in all the rectosigmoid biopsy samples from the same patient (such as SAA1 in case 4 and IL-8 in case 8), whereas others were only altered in some of these biopsy samples (i.e., SAA1 and PPAR- in case 3, IL-8 in case 4, and COX-2 in case 8). In addition, some of these alterations are restrict to the rectosigmoid regions, such as IL-8 in case 4, whereas others can be extended to other regions of the colon, such as SAA1 in case 4 (Fig. 2B).

View larger version (22K): [in this window] [in a new window]   Fig. 2 Distribution of alterations of gene expression in normal colon mucosa of individuals with a family history of colon cancer. A, altered gene expression in rectosigmoid biopsy samples from three individuals (cases 3, 4, and 8). Number of biopsy samples from each individual (n). Biopsy sample (box). B, altered gene expression in ascending (Asc), transverse (Trans), descending (Des), and rectosigmoid (S/R) colon. Indicated colon segments (box). Names of the genes analyzed (left of each row). Presence of altered gene expression in the corresponding samples/colon segments analyzed (shaded box).

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Approximately 5% to 10% of colorectal cancers occur among patients with one of the two autosomal dominant hereditary forms of colon (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer) or who have inflammatory bowel disease (11). Of the remaining colon cancers, 20% are associated with a family history of colon cancer, which is associated with a 2-fold increased risk of developing colon cancer (1). Although linkage to chromosomes 15q13-14 and 9q22.2-31.2 has been reported in a subset of patients with familial colorectal cancer (14), the genetic basis for most of these cases is not known. In this study, we have shown substantial alterations in the expression of PPAR-, IL-8, and SAA1 in the rectosigmoid MNCM from individuals with a family history of sporadic colon cancer, although these individuals had no detectable colon abnormalities. Our previous study showed that, in addition to PPAR-, IL-8, and SAA1, expressions of PPAR-, p21, OPN, COX-2, CXCR2, MCSF-1, and CD44 were also altered significantly in the MNCM of colon cancer patients when compared with normal controls without colon cancer, polyps, or family history. These observations suggest that altered expression of genes related to cancer development in the MNCM may be a sequential event and may occur earlier than the appearance of gross morphologic abnormalities. For example, altered expression of PPAR-, SAA1, and IL-8 may occur in MNCM of individuals who have not developed colon cancer, but are at high risk of doing so, whereas altered expressions of other genes, such as PPAR-, p21, OPN, COX-2, CXCR2, MCSF-1, and CD44, may occur later in MNCM of individuals who have already developed a colon cancer (10).

Genetic and epigenetic changes have been reported in macroscopically normal tissues for several neoplasms (15). For example, allelic loss has been shown in normal breast terminal ductal lobular units adjacent to primary breast cancers (16). Such allelic loss is associated with an increased risk of local recurrence (17). In addition, normal-appearing colonic mucosal cells from individuals with a prior colon cancer are more resistant to bile acid–induced apoptosis than mucosal cells from individuals with no prior colon cancer. (18, 19). Because apoptosis is important in colonic epithelium to eliminate cells with unrepaired DNA damage (20), reduction in apoptosis could result in the retention of DNA-damaged cells and increase the risk of carcinogenic mutations.

PPAR- is down-regulated in several carcinomas. Ligands of PPAR- inhibit cell growth and induce cell differentiation (21), and loss-of-function mutations in PPAR- have been reported in human colon cancer (22). Thus, our observation of down-regulation in PPAR- expression in MNCM may represent an early event that promotes colonic epithelial cell growth and inhibits cellular differentiation. In addition, PPAR- also negatively regulates inflammatory response (23). Inflammation favors tumorigenesis by stimulating angiogenesis and cell proliferation (24). Similarly, IL-8 and the acute-phase protein SAA1 modulate the inflammatory process (25, 26). Up-regulation of proinflammatory cytokines and acute phase proteins has been reported in the colon mucosa of individuals with inflammatory bowel disease (27, 28), who are at very high risk of developing colon cancer (29). Epidemiologic observations also suggest that chronic inflammation predisposes to colorectal cancer (30, 31). Thus, the observation of down-regulation of PPAR- and up-regulation of IL-8 and SAA1 in the normal mucosa of individuals with a family history of sporadic colon cancer and individuals with inflammatory bowel disease may indicate the involvement of common pathways leading to colon carcinogenesis in these two groups.

Our observation of altered expression of genes associated with cancer and inflammation in normal colonic mucosa in some individuals with a family history of colon cancer is consistent with the recent report of association of elevated serum C-reactive protein concentration before the development of colon cancer (32). These findings suggest that inflammation is a risk factor for the development of colon cancer in average-risk individuals (32). However, C-reactive protein is a nonspecific marker of inflammation that may indicate inflammation in tissues other than colon. In our study, we have analyzed the tissue where colon cancer arises and would be more specific in assessing the risk of developing colon cancer.

We do not know which cell type is responsible for the observed altered gene expression. There are many cell types in the colonic mucosa, including several types of mucosal epithelial cells, stromal cells, and blood-borne cells. Studies from our group and others have shown that the up-regulation of COX-2 protein in MNCM is localized primarily to the infiltrating macrophages and secondarily to the epithelial cells in aberrant crypt foci in the MNCM of APC^min mice (10, 33). From our previous studies of MNCM of APC^min mice, detection of the gene products that are up-regulated or down-regulated in MNCM by immunohistochemical staining was found to be technically difficult, perhaps because the secreted proteins, such as IL-8 and SAA1, are evanescent in tissue sections (10). Due to the limited amount of the biopsy samples and technical difficulties, we were unable to perform immunohistochemical staining to show the cell types contributing to the altered gene expression. If the absolute RNA quantities are sufficient, RNA in situ hybridization may be a better method to determine the cellular locations of alterations. Alternatively, laser microdissection followed by reverse transcription-PCR may be able to define the cell types involved. Regardless of the cell types responsible for the altered gene expression, our results show that relative to normal individuals without family history of colon cancer, altered gene expression is present in normal colon mucosa of some individuals with a family history of colon cancer, and these individuals are known to have an increased risk of developing colon cancer (11).

Among patients with altered gene expression in the rectosigmoid biopsy samples, some showed alterations in all biopsy samples (i.e., expression of SAA1 in cases 4 and 12), whereas others showed altered expression in some biopsy samples only (i.e., PPAR- in cases 2 and 3; Table 1). Because most samples were assayed with multiple genes in duplications to ensure the quality of cDNA, such heterogeneity is unlikely due to technical variation. We speculate that this heterogeneity might reflect the frequency and/or the distribution of "hotspots" in these individuals. It is possible that the individuals with altered gene expression in all rectosigmoid biopsy samples may have widespread molecular abnormalities in their rectosigmoid mucosa, whereas those with altered expression in some of the biopsy samples have discrete hotspots. Thus, individuals in the former group may have a global predisposition to development of colon polyps or cancer, whereas those in the latter group may have local predisposition. Whether the risks in developing colon cancer or polyps differ between these two groups is unknown. In addition, altered expression of different combination of genes were observed in the rectosigmoid biopsy samples of individuals in the family history group. This observation suggests that different molecular pathways may be involved in the early stages of colon carcinogenesis. Whether altered gene expression in certain molecular pathways is associated with higher risk of polyps or cancer also remains to be determined.

Consistent with the reports of more aberrant crypt foci (the preneoplastic colonic lesions) in the distal colon than in the proximal colon of the sporadic colon cancer patients and the carcinogen treated mice (34, 35), we found that most of the alterations in gene expression were found in the distal colon of the individuals from the family history group. We speculate that the distal colon mucosa of the susceptible individuals may be exposed to higher concentration of exogenous substances present in the stool than mucosa in other colon regions after most of the water is reabsorbed at the end of the large intestine, and such exposure may lead to higher rate of altered gene expression at this region.

We have shown that family history of colon cancer, but not age or sex, is the factor responsible for the observed differences in gene expression in the rectosigmoid mucosa of the two groups. The available information did not indicate any specific difference in diet or medication between these two groups of patients. However, we cannot eliminate the possibility that diet or medication affect gene expression without further study. Not all individuals with a family history of colon cancer will develop cancer or APs of the colon (1). Consistent with this clinical observation, our analysis also showed that not all the individuals with a family history of colon cancer have altered gene expression in MNCM. Because the genes analyzed in this study are involved in the development of colon cancer, we hypothesize that individuals with altered gene expression in the MNCM may be more susceptible to developing polyps or cancer than those without altered gene expression. To test this hypothesis, a prospective study with a larger number of study subjects will be needed. If such an association is confirmed, it may be possible to identify individuals at increased risk of developing colon cancer by using gene expression analysis of rectosigmoid biopsy samples. Theoretically, it is easier to identify individuals with global alterations in the MNCM than individuals with local alterations by analysis of random MNCM samples. However, if an appropriate panel of genes was selected for analysis using multiple samples, it may have enough predictive power to identify such patients.

	ACKNOWLEDGMENTS

 
We thank nurses Barb Wachtler and Jo Sandgren for their excellent assistance in obtaining the biopsy samples and Dr. Warren Browner for helpful suggestions and comments.

	FOOTNOTES

 
Grant support: Alden P. Yates Fund for colon cancer.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: C.-Y. Hao's current address is Department of Surgery, School of Oncology, Peking University, 52 Fu-Cheng-Lu Street, 100036, Peking, P.R. China.

Received 9/21/04; revised 11/ 9/04; accepted 11/18/04.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Smith RA, von Eschenbach AC, Wender R, et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001-testing for early lung cancer detection. CA Cancer J Clin 2001;51:38–75, quiz 77–80.[Abstract/Free Full Text]
2. Sonnenberg A, Delco F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000;133:573–84.[Abstract/Free Full Text]
3. Giordano TJ, Shedden KA, Schwartz DR, et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol 2001;159:1231–8.[Abstract/Free Full Text]
4. Kitahara O, Furukawa Y, Tanaka T, et al. Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res 2001;61:3544–9.[Abstract/Free Full Text]
5. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 2001;61:3124–30.[Abstract/Free Full Text]
6. Guda K, Cui H, Garg S, et al. Multistage gene expression profiling in a differentially susceptible mouse colon cancer model. Cancer Lett 2003;191:17–25.[CrossRef][Medline]
7. Muro S, Takemasa I, Oba S, et al. Identification of expressed genes linked to malignancy of human colorectal carcinoma by parametric clustering of quantitative expression data. Genome Biol 2003;4:R21.[CrossRef][Medline]
8. Tureci O, Ding J, Hilton H, et al. Computational dissection of tissue contamination for identification of colon cancer-specific expression profiles. Faseb J 2003;17:376–85.[Abstract/Free Full Text]
9. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256:668–70.[Abstract/Free Full Text]
10. Chen L-C, Hao C-Y, Chiu YSY, et al. Alteration of gene expression in normal appearing colon mucosa of APC^min mice and human cancer patients. Cancer Res 2004;64:3694–700.[Abstract/Free Full Text]
11. Burt R, Peterson GM. In: Young G, Rozen P, Levin B, Saunders, editors. In Prevention and early detection of colorectal cancer. Philadelphia; 1996. p. 171–94.
12. Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 2004;292:1480–9.[Abstract/Free Full Text]
13. Owen DB. Noncentral t and tolerance limits. In: Brimbaum ZW, editor. Handbook of statistical tables. Reading (MA): Addison-Wesley, 1962; 1962. p. 108–27.
14. Wiesner GL, Daley D, Lewis S, et al. A subset of familial colorectal neoplasia kindreds linked to chromosome 9q22.2-31.2. Proc Natl Acad Sci U S A 2003;100:12961–5.[Abstract/Free Full Text]
15. Tycko B. Genetic and epigenetic mosaicism in cancer precursor tissues. Ann N Y Acad Sci 2003;983:43–54.[Abstract/Free Full Text]
16. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996;274:2057–9.[Abstract/Free Full Text]
17. Li Z, Moore DH, Meng ZH, Ljung BM, Gray JW, Dairkee SH. Increased risk of local recurrence is associated with allelic loss in normal lobules of breast cancer patients. Cancer Res 2002;62:1000–3.[Abstract/Free Full Text]
18. Bernstein C, Bernstein H, Garewal H, et al. A bile acid-induced apoptosis assay for colon cancer risk and associated quality control studies. Cancer Res 1999;59:2353–7.[Abstract/Free Full Text]
19. Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995;55:1811–6.[Abstract/Free Full Text]
20. Payne CM, Bernstein H, Bernstein C, Garewal H. Role of apoptosis in biology and pathology: resistance to apoptosis in colon carcinogenesis. Ultrastruct Pathol 1995;19:221–48.[Medline]
21. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, Matsuzawa Y. Peroxisome proliferator-activated receptor induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999;90:75–80.[CrossRef][Medline]
22. Sarraf P, Mueller E, Smith WM, et al. Loss-of-function mutations in PPAR associated with human colon cancer. Mol Cell 1999;3:799–804.[CrossRef][Medline]
23. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPAR and PPAR negatively regulate specific subsets of lipopolysaccharide and IFN- target genes in macrophages. Proc Natl Acad Sci U S A 2003;100:6712–7.[Abstract/Free Full Text]
24. Nakajima N, Kuwayama H, Ito Y, Iwasaki A, Arakawa Y. Helicobacter pylori, neutrophils, interleukins, and gastric epithelial proliferation. J Clin Gastroenterol 1997;25 Suppl 1:S198–202.
25. Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 2002;72:9–18.[Abstract/Free Full Text]
26. Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 2000;7:64–9.[CrossRef][Medline]
27. Niederau C, Backmerhoff F, Schumacher B. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology 1997;44:90–107.[Medline]
28. Keshavarzian A, Fusunyan RD, Jacyno M, Winship D, MacDermott RP, Sanderson IR. Increased interleukin-8 (IL-8) in rectal dialysate from patients with ulcerative colitis: evidence for a biological role for IL-8 in inflammation of the colon. Am J Gastroenterol 1999;94:704–12.[CrossRef][Medline]
29. Bachwich DR, Lichtenstein GR, Traber PG. Cancer in inflammatory bowel disease. Med Clin North Am 1994;78:1399–412.[Medline]
30. Rhodes JM, Campbell BJ. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med 2002;8:10–6.[CrossRef][Medline]
31. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002;359:331–40.[CrossRef][Medline]
32. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. Jama 2004;291:585–90.[Abstract/Free Full Text]
33. Hull MA, Booth JK, Tisbury A, et al. Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br J Cancer 1999;79:1399–405.[CrossRef][Medline]
34. Shpitz B, Bomstein Y, Mekori Y, et al. Aberrant crypt foci in human colons: distribution and histomorphologic characteristics. Hum Pathol 1998;29:469–75.[CrossRef][Medline]
35. Salim EI, Wanibuchi H, Morimura K, et al. Induction of tumors in the colon and liver of the immunodeficient (SCID) mouse by 2-amino-3-methylimidazo[4,5f] quinoline (IQ)-modulation by long-chain fatty acids. Carcinogenesis 2002;23:1519–29.[Abstract/Free Full Text]

This article has been cited by other articles:

				A. C.J. Polley, F. Mulholland, C. Pin, E. A. Williams, D. M. Bradburn, S. J. Mills, J. C. Mathers, and I. T. Johnson Proteomic Analysis Reveals Field-Wide Changes in Protein Expression in the Morphologically Normal Mucosa of Patients with Colorectal Neoplasia. Cancer Res., July 1, 2006; 66(13): 6553 - 6562. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hao, C.-Y. Articles by Chen, L.-C. Search for Related Content PubMed PubMed Citation Articles by Hao, C.-Y. Articles by Chen, L.-C.